A Phase 1 interventional study of Pirtobrutinib and Digoxin in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-21.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The main purpose of this study is to evaluate the effect of Pirtobrutinib (LOXO-305) on multiple oral doses of digoxin (P-gp substrate) when administered as single and multiple doses by collecting the blood samples and conducting the blood tests to measure how much digoxin is in the bloodstream and how the body handles and eliminates it in healthy participants. The study will also evaluate the safety and tolerability of Pirtobrutinib. Participants will stay in this study for up to 58 days, including screening.
Eli Lilly and Company is the lead sponsor of 2,109 studies on the registry; 153 are open to participants now.
Of its 540 completed or terminated interventional studies of FDA-regulated products, 358 (66%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received oral dose of * 0.25 mg digoxin twice daily (BID) on Day 1 * 0.25 mg digoxin once daily (QD) from Day 2 to Day 7 * 200 mg Pirtobrutinib in combination with 0.25 mg digoxin QD starting from Day 8 to Day 16
Drug: Pirtobrutinib · Drug: Digoxin
Administered Orally.
Also known as: LOXO-305, LY3527727
Administered Orally.
Pharmacokinetics (PK): Area Under the Concentration-Time Curve From Hour 0 to the Last Measurable Concentration (AUC[0-t]) of Digoxin in Plasma
PK: AUC\[0-t\] of Digoxin was reported.
Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Area Under the Concentration During a Dosing Interval (AUC [Tau]) of Digoxin in Plasma
PK: AUC \[tau\] of Digoxin was reported.
Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Apparent Systemic Clearance (CL/F) of Digoxin in Plasma
PK: CL/F of Digoxin in plasma was reported.
Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Maximum Observed Plasma Concentration (Cmax) of Digoxin in Plasma
PK: Cmax of Digoxin was reported.
Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Digoxin in Plasma
PK: Tmax of Digoxin was reported.
Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Mean Residence Time (MRT) of Digoxin in Plasma
PK: MRT of Digoxin was reported.
Time frame: Day 7 and Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Cumulative Amount of Drug Excreted Unchanged in Urine (Ae) of Digoxin
PK: Ae of Digoxin in urine was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.
Time frame: Day 7 and Day 16: Predose, 6, 12, 24 hours post dose
PK: Fraction of Digoxin Excreted Unchanged in Urine (Fe) Expressed as Percentage of Dose Excreted
PK: Fe of Digoxin was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.
Time frame: Day 7 and Day 16: Predose, 6, 12, 24 hours post dose
PK: Renal Clearance (CLr) of Digoxin in Plasma
PK: CLr of Digoxin in plasma was reported.
Time frame: Day 7: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Area Under the Concentration From Hour 0 to the Last Measurable Concentration (AUC0-t) of Pirtobrutinib in Plasma
PK: AUC\[0-t\] of Pirtobrutinib was reported.
Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Area Under the Concentration During a Dosing Interval (AUCtau) of Pirtobrutinib in Plasma
PK: AUCtau of Pirtobrutinib was reported.
Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib in Plasma
PK: CL/F of Pirtobrutinib in plasma was reported.
Time frame: Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Maximum Observed Plasma Concentration (Cmax) of Pirtobrutinib in Plasma
PK: Cmax of Pirtobrutinib was reported.
Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Time to Maximum Observed Plasma Concentration (Tmax) of Pirtobrutinib in Plasma
PK: Tmax of Pirtobrutinib was reported.
Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
PK: Mean Residence Time (MRT) of Pirtobrutinib in Plasma
PK: MRT of Pirtobrutinib was reported.
Time frame: Day 8: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, and 24 hours postdose; Day 16: Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12, 24, 48, 72, and 96 hours postdose
| Milestone | Digoxin + Pirtobrutinib |
|---|---|
| Started | 16 |
| Received at least 1 dose of study drug | 16 |
| Completed | 15 |
| Not completed | 1 |
| Withdrew: Adverse event | 1 |
PK: AUC\[0-t\] of Digoxin was reported.
| hour*nanogram per milliliter (h*ng/mL) | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 14.6 ± 21.1 |
| Day 8 | 17.1 ± 19.6 |
| Day 16 | 48.9 ± 22.0 |
PK: AUC \[tau\] of Digoxin was reported.
| h*ng/mL | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 14.7 ± 21.1 |
| Day 8 | 17.2 ± 19.6 |
| Day 16 | 20.4 ± 23.4 |
PK: CL/F of Digoxin in plasma was reported.
| liter per hour(L/h) | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 17.0 ± 21.1 |
| Day 8 | 14.5 ± 19.6 |
| Day 16 | 12.2 ± 23.4 |
PK: Cmax of Digoxin was reported.
| nanogram per milliliter (ng/mL) | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 1.57 ± 26.1 |
| Day 8 | 2.38 ± 27.7 |
| Day 16 | 2.45 ± 42.0 |
PK: Tmax of Digoxin was reported.
| hour | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 1.27 (0.750 to 3.00) |
| Day 8 | 1.25 (0.750 to 3.00) |
| Day 16 | 1.00 (0.750 to 2.50) |
PK: MRT of Digoxin was reported.
| hours | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 52.2 ± 49.1 |
| Day 8 | 65.2 ± 47.2 |
| Day 16 | 60.4 ± 52.5 |
PK: Ae of Digoxin in urine was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.
| mg | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 0.123 ± 23.3 |
| Day 16 | 0.148 ± 18.2 |
PK: Fe of Digoxin was reported. The urine sampling time points from pre-dose through 24 hours post-dose were used to assess this outcome.
| percentage of dose excreted in urine | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 49.2 ± 23.3 |
| Day 16 | 59.4 ± 18.2 |
PK: CLr of Digoxin in plasma was reported.
| L/h | Digoxin + Pirtobrutinib |
|---|---|
| Day 7 | 8.35 ± 15.0 |
| Day 16 | 7.28 ± 17.0 |
PK: AUC\[0-t\] of Pirtobrutinib was reported.
| h*ng/mL | Digoxin + Pirtobrutinib |
|---|---|
| Day 8 | 48400 ± 16.3 |
| Day 16 | 189000 ± 25.8 |
PK: AUCtau of Pirtobrutinib was reported.
| h*ng/mL | Digoxin + Pirtobrutinib |
|---|---|
| Day 8 | 48600 ± 16.3 |
| Day 16 | 106000 ± 21.0 |
PK: CL/F of Pirtobrutinib in plasma was reported.
| L/h | Digoxin + Pirtobrutinib |
|---|---|
| PK: Apparent Systemic Clearance (CL/F) of Pirtobrutinib in Plasma | 1.89 ± 21.0 |
PK: Cmax of Pirtobrutinib was reported.
| ng/mL | Digoxin + Pirtobrutinib |
|---|---|
| Day 8 | 4330 ± 17.1 |
| Day 16 | 7530 ± 17.9 |
PK: Tmax of Pirtobrutinib was reported.
| hours | Digoxin + Pirtobrutinib |
|---|---|
| Day 8 | 2.50 (1.00 to 3.00) |
| Day 16 | 2.50 (0.500 to 4.00) |
PK: MRT of Pirtobrutinib was reported.
| hours | Digoxin + Pirtobrutinib |
|---|---|
| Day 8 | 22.6 ± 18.7 |
| Day 16 | 30.5 ± 17.5 |
Collected over Baseline up to Day 27. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 0.25 mg Digoxin | 0/16 (0%) | 0/16 (0%) | 5/16 (31.3%) |
| 200 mg Pirtobrutinib + 0.25 mg Digoxin | 0/16 (0%) | 0/16 (0%) | 1/16 (6.3%) |
| Event | 0.25 mg Digoxin | 200 mg Pirtobrutinib + 0.25 mg Digoxin |
|---|---|---|
| Medical device site erythemaGeneral disorders | 2/16 | 0/16 |
| Visual impairmentEye disorders | 0/16 | 1/16 |
| Abdominal discomfortGastrointestinal disorders | 0/16 | 1/16 |
| Abdominal distensionGastrointestinal disorders | 1/16 | 0/16 |
| DiarrhoeaGastrointestinal disorders | 1/16 | 0/16 |
| FlatulenceGastrointestinal disorders | 1/16 | 0/16 |
| NauseaGastrointestinal disorders | 1/16 | 0/16 |
| Medical device site injuryGeneral disorders | 1/16 | 0/16 |
| Medical device site pruritusGeneral disorders | 1/16 | 0/16 |
| Vascular access site haematomaInjury, poisoning and procedural complications | 1/16 | 0/16 |
All enrolled participants.
| Age, Continuous(years) | Digoxin + Pirtobrutinib |
|---|---|
| Mean | 41.8 ± 8.25 |
| Sex: Female, Male(Participants) | Digoxin + Pirtobrutinib |
|---|---|
| Female | 2 |
| Male | 14 |
| Ethnicity (NIH/OMB)(Participants) | Digoxin + Pirtobrutinib |
|---|---|
| Hispanic or Latino | 4 |
| Not Hispanic or Latino | 12 |
| Unknown or Not Reported | 0 |
| Race (NIH/OMB)(Participants) | Digoxin + Pirtobrutinib |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 0 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 4 |
| White | 12 |
| More than one race | 0 |
| Unknown or Not Reported | 0 |
| Region of Enrollment(Participants) | Digoxin + Pirtobrutinib |
|---|---|
| United States | 16 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2021 to primary completion in Jun 2021, 2 months.
Results were first posted in Feb 2025, 3 years 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pirtobrutinib